Ullah Waqas, Meizinger Casey, Ali Zain, Panchal Ankur, Saeed Rehan, Haas Donald C, Rame Eduardo
Department of Internal Medicine, Abington Jefferson Health, Abington, PA 19001, United States.
Department of Internal Medicine, University of Pittsburgh, Pittsburgh, PA 15213, United States.
World J Cardiol. 2020 Nov 26;12(11):550-558. doi: 10.4330/wjc.v12.i11.550.
Given current evidence, the effect of left ventricular assist device (LVAD) implantation on pulmonary function tests remains controversial.
To better understand the factors contributing to the changes seen on pulmonary function testing and the correlation with pulmonary hemodynamics after LVAD implantation.
Electronic databases were queried to identify relevant articles. The summary effect size was estimated as a difference of overall means and standard deviation on a random-effects model.
A total of four studies comprising 219 patients were included. The overall mean forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion lung capacity of carbon monoxide (DLCO) after LVAD implantation were significantly lower by 0.23 L (95%CI: 0.11-0.34, = 00002), 0.18 L (95%CI: 0.03-0.34, = 0.02), and 3.16 mmol/min (95%CI: 2.17-4.14, < 0.00001), respectively. The net post-LVAD mean value of the cardiac index was significantly higher by 0.49 L/min/m (95%CI: 0.31-0.66, < 0.00001) compared to pre-LVAD value. The pulmonary capillary wedge pressure and pulmonary vascular resistance were significantly reduced after LVAD implantation by 8.56 mmHg (95%CI: 3.78-13.35, = 0.0004), and 0.83 Woods (95%CI: 0.11-1.55, = 0.02), respectively. There was no significant difference observed in the right atrial pressure after LVAD implantation (0.61 mmHg, 95%CI: -2.00 to 3.32, = 0.65). Overall findings appear to be driven by studies using HeartMateII devices.
LVAD implantation might be associated with a significant reduction of the spirometric measures, including FEV1, FVC, and DLCO, and an overall improvement of pulmonary hemodynamics.
根据目前的证据,植入左心室辅助装置(LVAD)对肺功能测试的影响仍存在争议。
为了更好地了解导致LVAD植入后肺功能测试变化的因素以及与肺血流动力学的相关性。
查询电子数据库以识别相关文章。汇总效应量估计为随机效应模型上总体均值和标准差的差异。
共纳入四项研究,包括219例患者。LVAD植入后一秒用力呼气量(FEV1)、用力肺活量(FVC)和一氧化碳弥散量(DLCO)的总体均值分别显著降低0.23L(95%CI:0.11 - 0.34,P = 0.0002)、0.18L(95%CI:0.03 - 0.34,P = 0.02)和3.16mmol/min(95%CI:2.17 - 4.14,P < 0.00001)。与LVAD植入前相比,LVAD植入后心脏指数的净均值显著升高0.49L/min/m²(95%CI:0.31 - 0.66,P < 0.00001)。LVAD植入后肺毛细血管楔压和肺血管阻力分别显著降低8.56mmHg(95%CI:3.78 - 13.35,P = 0.0004)和0.83Wood单位(95%CI:0.11 - 1.55,P = 0.02)。LVAD植入后右心房压力无显著差异(0.61mmHg,95%CI: - 2.00至3.32,P = 0.65)。总体研究结果似乎受使用HeartMateII装置的研究驱动。
LVAD植入可能与肺活量测定指标(包括FEV1、FVC和DLCO)的显著降低以及肺血流动力学的总体改善有关。